Main indications and suitable groups of Fenelidone/Cashenda

Finerenone is a new type of mineralocorticoid receptor antagonist (MRA), mainly used to treat chronic kidney disease (CKD) related to type 2 diabetes (T2D). It improves kidney function and effectively reduces the occurrence of cardiovascular events by inhibiting mineralocorticoid receptors. The indications for fenelidone are mainly in patients with chronic kidney disease who have T2D, especially those with cardiovascular risk.

1. Chronic kidney disease (CKD): Fenelidone has been approved for the treatment of chronic kidney disease associated with type 2 diabetes, especially in patients with persistent decline in eGFR. Chronic kidney disease is a common complication in patients with T2D, and long-term renal function damage may lead to further deterioration of kidney function and even the development of end-stage renal disease (ESRD). Fennelidone can effectively improve the filtration function of the kidneys and slow down the progression of the disease.

2. Cardiovascular risk: Fenelidone has also been shown to significantly reduce the risk of cardiovascular events in T2D patients, especially heart failure hospitalization, myocardial infarction, etc. For these patients with a history of or high risk for cardiovascular disease, fenelidone not only helps control the progression of kidney disease but also reduces the incidence of cardiovascular events.

3. Patients with persistent decline in eGFR: For those T2D patients with persistent decline in eGFR, the therapeutic effect of fenelidone is particularly obvious. Studies have shown that fenelidone can slow down the decline of eGFR and delay the progression of patients to end-stage renal disease.

In summary, fenelidone is suitable for patients with chronic kidney disease who have type 2 diabetes, especially those with persistent decline in eGFR and associated cardiovascular risk. By improving renal function, reducing proteinuria, and reducing the incidence of cardiovascular events, fenelidone provides patients with an effective treatment option.

Keyword tags: Finerenone,Finerenone, indications, chronic kidney disease, T2D, cardiovascular risk, eGFR, proteinuria, heart failure

Reference materials:https://www.medicines.org.uk/emc/product/13437/smpc